后基因組時代，功能蛋白質組研究是臨床醫學非常重要的研究方向。通過功能蛋白質研究，發現新的生物標志物，用于疾病的臨床診斷，藥物研發，藥物臨床試驗，對臨床醫學產生實質性的推動。
典型的臨床樣本是稀缺的科學研究材料，臨床研究需要定量的研究工具，因而在臨床研究中針對微量樣本，實現定量檢測是技術平臺必不可少的要求。
最近歐洲最頂級的醫學研究中心薩拉曼卡大學醫學院癌癥研究中心，血液科的臨床科學家，在頂級血液病雜志haematologica發表方法學文章，A
novel nano-immunoassay method for quantification of proteins from CD138
purified myeloma cells: biological and clinical
utility。該文nano-immunoassay method為ProteinSimple Wes系統。
該研究選用63例多發性骨髓瘤，并分選其中CD138陽性細胞，提取蛋白質及核酸用于后續檢測。
文章中，作者檢測了包括內參蛋白GAPDH在內的13種白質
使用Wes系統建立絕對定量檢測模型
定量分析63例臨床樣本中13種白質的表達水平
文中作者闡述了使用Wes nano-immunoassay method進行此項臨床研究的原因：
1.The recent development of a method based on the combination of capillary nano-electrophoresis with immunoassay (CNIA), also known as Simple Western, requires only very small amounts of sample to be able to measure protein expression 3,7. This technical advance makes it possible to analyze the expression of 50-100 proteins in a single MM sample.
使用微量樣本，因而使得一份多發性骨髓瘤樣本可以進行50-100個蛋白檢測成為可能。
2.Here we present a method for the accurate and robust quantification of the expression of multiple proteins extracted from CD138-purified multiple myeloma samples frozen in RLT Plus buffer, which is commonly used for nucleic acid preservation and isolation
準確定量CD138分選細胞蛋白質表達
3.This makes the CNIA platform a fast, effective and accurate tool for exploring the impact of different proteins on MM survival and for investigating new protein biomarkers that could help predict the response to new drugs that directly target specific proteins.